Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05906628 · ClinicalTrials.gov registry record · Phase 2
Topical Ruxolitinib Evaluation in Chronic Hand Eczema
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 186
- Enrollment target
NCT05906628 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 186 participants.
The verdict
NCT05906628, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 186 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).
Interventions
- DRUG Vehicle
- DRUG Ruxolitinib cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2023-07-31 |
| Est. Completion | 2024-12-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05906628
The ClinicalTrials.gov registry entry for NCT05906628 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT05906628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05906628 about?
NCT05906628 is a clinical study titled "Topical Ruxolitinib Evaluation in Chronic Hand Eczema". The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).
What is the current status of trial NCT05906628?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2023-07-31. Estimated completion is 2024-12-13.
What interventions are being tested in trial NCT05906628?
The interventions under investigation include: Vehicle (DRUG), Ruxolitinib cream (DRUG).
Who is sponsoring clinical trial NCT05906628?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.